68 terminated. 68 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 68 | Terminated 68 |
| Phase 2 | 15 | Terminated 15 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) ION269 - Alzheimer Disease, Down Syndrome | Phase 1 | Terminated | Ionis Pharmaceuticals, Inc. | 1 | 2024-12-20 | 2026-02-20 |
| Ultrasonic Neuromodulation for Treatment of Cognitive Impairment Diadem prototype - Alzheimer Disease, Dementia | Phase 1 / Phase 2 | Terminated | University of Utah | 1 | 2024-08-18 | 2025-05-25 |
| A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD - Alzheimer Disease | Phase 1 | Terminated | Alzheimer's Disease Expert Lab (ADEL), Inc. | 42 | 2024-02-06 | 2026-04-30 |
| Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) WVE-004 10 mg Q12W - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 8 | 2022-12-14 | 2026-09-09 |
| Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease DSPE-DOTA-Gd Liposomal Injection - Alzheimer Disease | Phase 1 | Terminated | Alzeca Biosciences, Inc. | 16 | 2022-11-09 | 2025-08-13 |
| Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD Deutetrabenazine Oral Tablet [Austedo], Placebo oral tablet - Huntington Disease | Phase 1 | Terminated | Fundacion Huntington Puerto Rico | 36 | 2022-01-21 | 2025-02-27 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline SDI-118, Placebo - Cognitive Decline | Phase 1 | Terminated | Syndesi Therapeutics | 5 | 2021-09-23 | 2022-04-22 |
| A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes PBFT02 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Terminated | Passage Bio, Inc. | 30 | 2021-09-14 | 2026-10-29 |
| Tricaprilin Liquid Formulation PK Study AC-1202, AC-OLE-01, AC-OLE-02 - Alzheimer Disease | Phase 1 | Terminated | Cerecin | 71 | 2021-08-31 | 2023-10-17 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 1 | Terminated | Asceneuron Pty Ltd. | 25 | 2021-06-02 | 2023-01-17 |
| MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease JNJ-40346527, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Terminated | University of Oxford | 2 | 2021-04-07 | 2024-05-09 |
| Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) SNK01 - Alzheimer Disease, Neuro-Degenerative Disease | Phase 1 | Terminated | NKGen Biotech, Inc. | 10 | 2021-01-06 | 2024-03-01 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease WVE-120101 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 27 | 2020-04-13 | 2022-02-09 |
| Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease Fecal Microbiota Transplant - Alzheimer Disease | Phase 1 | Terminated | University of Wisconsin, Madison | 5 | 2019-11-14 | 2020-07-24 |
| Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study Allopregnanolone - Alzheimer Dementia | Phase 1 | Terminated | University of Arizona | 6 | 2019-10-01 | 2026-03-13 |
| Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease WVE-120102 - Huntington Disease | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 36 | 2019-09-24 | 2022-02-09 |
| PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan - Dementia | Phase 1 | Terminated | National Institute of Mental Health (NIMH) | 13 | 2019-07-03 | 2024-05-01 |
| A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects PU-AD, Placebo - Alzheimer's Disease | Phase 1 | Terminated | Samus Therapeutics, Inc. | 40 | 2019-06-24 | 2023-04-18 |
| Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD Lu AF20513, booster vaccine - Alzheimer Disease | Phase 1 | Terminated | H. Lundbeck A/S | 3 | 2018-12-12 | 2020-02-21 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
Showing 20 of 68. Sign in to see all of them.
Alzheimer Disease (49) · Cognitive Dysfunction (10) · Dementia (6) · Huntington Disease (6) · Cognition Disorders (4) · Parkinson Disease (3) · AIDS Dementia Complex (2) · Brain Diseases (2) · Delirium (2) · Frontotemporal Dementia (2) · Mental Disorders (2) · Multiple Sclerosis (2) · Neurodegenerative Diseases (2) · Pick Disease of the Brain (2)
Mental Disorders (66) · Nervous System Diseases (62) · Central Nervous System Diseases (60) · Brain Diseases (59) · Neurodegenerative Diseases (57) · Dementia (54) · Tauopathies (48) · Cognition Disorders (15) · Basal Ganglia Diseases (9) · Movement Disorders (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Chorea (6) · Dyskinesias (6)
Donepezil (3) · GSK2647544 (2) · alicapistat (2) · ispronicline (2) · (2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine (1) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (1) · 6-chloro-2-(4'-iodophenyl)-3-(N,N-diethyl)imidazo(1,2-a)pyridine-3-acetamide (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · AC-1202 (1) · Dexmedetomidine (1) · Drug Interactions (1) · Escitalopram (1) · Fecal Microbiota Transplantation (1) · GABA Agonists (1)
Institute for Neurodegenerative Disorders (8) · Wave Life Sciences USA, Inc. (5) · H. Lundbeck A/S (4) · AbbVie (2) · AstraZeneca (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Johns Hopkins University (2) · Merck Sharp & Dohme LLC (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Abbott (1) · Alzeca Biosciences, Inc. (1) · Alzheimer's Disease Expert Lab (ADEL), Inc. (1) · Annovis Bio Inc. (1) · Asceneuron Pty Ltd. (1)
United States (40) · United Kingdom (12) · Germany (8) · Australia (7) · France (6) · Canada (5) · Denmark (4) · Poland (4) · Finland (3) · Spain (3) · Sweden (3) · Japan (2) · Netherlands (2) · Austria (1) · Brazil (1)
Danna L Jennings, MD (5) · Danna Jennings, MD (3) · Nuno Mendonca, MD (2) · Adam Boxer, MD, PhD (1) · Alan J Lerner, MD (1) · Barbara Bendlin, PhD (1) · Barry Reisberg (1) · Beatrice Rendenbach-Mueller, PhD (1) · Beau Nakamoto, MD PhD (1)
PMID 29480210, PMID 30052328, PMID 32250312, PMID 22766391, PMID 27582220, PMID 34389161, PMID 36281667, PMID 38567735, PMID 39939891
2014 (3), 2009 (1), 2015 (1), 2018 (1), 2023 (1)